课题基金 / 基金详情

项目摘要

项目成果

Dao Pan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of the Real-time Quantitative PCR Core is to assist investigators in evaluating gene transfer efficiency and transgene expression in target cells for projects in the Gene Therapy for Metabolic Disorders program. As initially demonstrated by a gene therapy clinical trial ("Lymphocyte gene therapy for Hunter syndrome), this technique fills a very significant scientific need, to accurately quantitate the presence of a gene, and to measure its expression by reverse transcriptase-PCR (RT-PCR) with a high level of sensitivity and reproducability. This core will assist investigators in designing assay systems (paired oligonucleotide primers and an internal TaqMan probe, Black Hole Quencher probe, or SYBR Green), as well as accomplish the actual assays of research specimens. The availability of a core facility accomplishing assays for common biologic systems (e.g., gene and gene products for OTC, MPS I, and MPS VII mouse models) eliminates redundancy and provides a greater level of quality assurance. The new, quantitative technology also provides sensitive methods for "safety assays" (e.g., for lentiviral vector RCR) that are much faster, reliable and inexpensive in comparison to existing culture approaches. The technique also provides a method of quantitating gene products (RT-PCR) for which there are no existing assays, or for DNA sequences that do not yield a translational or transcriptional end product (as might be needed for transposon vectors).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing CNS drug delivery via epigenetic modulation
Manipulation of microRNA for CNS delivery: implication to treatment of neurological LSD
Gaucher disease:Treatment of neurodegenerative disease
Gaucher disease:Treatment of neurodegenerative disease
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: